Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHTCF.L Regulatory News (HTCF)

  • There is currently no data for HTCF

Monthly Performance Review

18 Mar 2015 07:00

RNS Number : 7048H
BlueCrest AllBlue Fund Ltd
18 March 2015
Β 

ο»Ώ

FOR IMMEDIATE RELEASE

Β 

18 March 2015

Β 

BLUECREST ALLBLUE FUND LIMITED

MONTHLY PERFORMANCE REVIEW FOR FEBRUARY 2015

Β 

"Building on January's gains"

Β 

BlueCrest AllBlue Fund Limited (BCAB) rose by 0.6% in February, building on January's gains. This brings the year to date return to 1.7% (Sterling Class NAV). The rolling 12 month return was 7.3%. The volatility of returns remains very low, with the annualised 12 month volatility falling to just 1.7% in February.

Β 

A better environment for risk assets prevailed through most of February. Equities in developed markets saw some very strong gains of 5-7%, although emerging markets trailed this strength. Oil also bounced sharply after 6 months of steep losses. Bonds, on the other hand, gave back much of their sharp rally of January with US and UK yields rising 30-40bp. Eurozone government bonds, however, were supported by the announcement of QE in Europe and the temporary resolution of the Greek standoff.

Β 

"Credit was the strongest performing fund"

Β 

Five of the seven strategies were positive in February. BlueCrest Multi Strategy Credit and BlueCrest Emerging Markets were the strongest two funds, both of which gained close to 2% for the month. Interestingly, it was the two equity funds that saw the losses, despite the very strong equity market backdrop.

Β 

Neither of the two equity strategies saw large losses but their returns emphasised the generally low correlation of both funds to broader equity markets. BlueCrest Quantitative Equity always has a net position tightly bounded around zero and the discretionary BlueCrest Equity Strategies Fund typically has a net position between +/- 10%. As a result, large market-based moves should not unduly impact their overall returns, and so it proved in February. Rather, in both funds it was generally the reversals and volatility in macro themes, such as the oil price, that triggered a variety of modest losses.

Β 

In contrast, the equity exposures in BlueTrend were the strongest contributor to that fund's returns. BlueTrend entered February with a long directional bias to equities and added to that position through the month. Unsurprisingly, bond strategies detracted as they too were long biased but overall only around one sixth of January's strong gains from bonds were given back. Overall, BlueTrend recorded a modest gain and risk levels rose gently through the month.

Β 

BlueCrest Multi Strategy Credit was the strongest performing fund in February, gaining 1.9%. It was a generally benign month in the credit markets, with both investment grade and high yield spreads tightening, good primary issuance and positive flows into the sector. The fund achieved gains across most strategies with particular success in long/short trading where earnings news and corporate announcements played out as expected. Risk levels in the fund were increased modestly from their previously muted levels as uncertainty around geopolitics and central bank policies eased. However, the fund retains downside protection in place.

Β 

Several changes were made to allocations for March. BlueCrest Capital International was reduced by 1.5% and BlueCrest Multi Strategy Credit by 2% with those monies allocated to BlueCrest Equity Strategies (+0.5%), BlueCrest Quantitative Equity (+1.5%) and BlueTrend (+1.5%). As a result, systematic strategies rose to 35% of AllBlue.

Β 

"The buyback programme was generally quiet"

Β 

The share price has remained very stable relative to the net asset value during the month, with the discount drifting between 4.5% and 5%. Natural demand was consistently seen at around a 5% discount and so the buyback programme was generally quiet in February. The Company expects to release its annual financial statements around the middle of April.

Β 

Β 

Disclaimer:

This document is directed only at: (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005; or (ii) high net worth bodies corporate, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and persons who receive this document who do not fall within (i) or (ii) above should not rely on or act upon this document.

Β 

This document is issued by BlueCrest AllBlue Fund Limited (the "Company") to and for the information of its existing shareholders and does not in any jurisdiction constitute investment advice or an invitation to invest in the shares or any other securities of the Company or any other entity (body corporate or otherwise).

Β 

The Company has used reasonable care to ensure that the information included in this document is accurate at the date of its issue, but does not undertake to update or revise the information, including any information relating to AllBlue Limited and its underlying funds (the "Funds") provided by BlueCrest Capital Management (UK) LLP or any member of the BlueCrest group of companies (as applicable) ("BlueCrest"), or guarantee the accuracy of such information. To the extent permitted by law neither the Company, the Funds, BlueCrest nor their directors or officers shall be liable for any loss or damage that anyone may suffer in reliance on such information.

Β 

The information in this document may be changed by the Company at any time. Past performance cannot be relied on as a guide to future performance. The Company's investment strategy is speculative and entails substantial risks. The value of an investment may go down as well as up and some or all of the total amount invested may be lost. This document may not, in whole or in part, directly or indirectly, be taken, transmitted or distributed into the United States of America, its territories or possessions or made available to any national, resident or citizen of the United States of America or any other jurisdiction where applicable laws prohibit its release, distribution or publication. Any failure to comply with these restrictions may be a violation of the law in relevant jurisdictions.

Β 

JTC (Guernsey) Limited

Secretary

Β 

Tel: Guernsey 01481 702400

Β 

END OF ANNOUNCEMENT

E&OE - in transmission

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
STRDDLFFEXFBBBF
Date   Source Headline
1st Nov 20232:02 pmRNSCompany Update
27th Oct 20235:30 pmRNSHighbridge Tactical Credit Fund
18th Oct 20231:37 pmRNSCompany Update
3rd Oct 20239:36 amRNSDirector Declaration
28th Apr 20232:33 pmRNSTotal Voting Rights
17th Apr 20237:00 amRNSShares in issue
30th Mar 20235:02 pmRNSHalf-year Report
29th Mar 20232:11 pmRNSReturn of Capital
29th Mar 20232:08 pmRNSCash Distribution
17th Mar 20234:35 pmRNSPrice Monitoring Extension
17th Mar 20237:00 amRNSDirector Declaration
16th Mar 20237:00 amRNSCompany Update and Return of Capital Information
15th Mar 20234:36 pmRNS2019 Redemption Portfolio
15th Mar 20234:30 pmRNSNet Asset Value(s)
7th Mar 20234:35 pmRNSPrice Monitoring Extension
13th Feb 20239:00 amRNSChange of Registered Office
2nd Dec 202211:44 amRNSResult of AGM
21st Nov 20223:05 pmRNSHolding(s) in Company
9th Nov 20227:00 amRNSNotice of AGM
8th Nov 20224:00 pmRNSNet Asset Value(s)
8th Nov 20224:00 pmRNS2019 Redemption Portfolio
7th Nov 20225:00 pmRNS2019 Redemption Portfolio
7th Nov 20224:58 pmRNSNet Asset Value(s)
2nd Nov 20227:00 amRNSDistribution
31st Oct 20223:22 pmRNSAnnual Financial Report
20th Oct 202210:47 amRNSAudit Opinion
18th Oct 202211:04 amRNSNet Asset Value(s)
18th Oct 202211:03 amRNS2019 Redemption Portfolio
25th Aug 20224:50 pmRNSNet Asset Value(s)
25th Aug 20224:41 pmRNS2019 Redemption Portfolio
1st Aug 20229:51 amRNS2019 Redemption Portfolio
1st Aug 20229:45 amRNSNet Asset Value(s)
5th Jul 202211:09 amRNS2019 Redemption Portfolio
5th Jul 202211:03 amRNSNet Asset Value(s)
1st Jun 202211:22 amRNSNet Asset Value(s)
1st Jun 202211:20 amRNS2019 Redemption Portfolio
7th Apr 20228:38 amRNSNet Asset Value(s)
7th Apr 20228:24 amRNS2019 Redemption Portfolio
25th Mar 202211:22 amRNSNet Asset Value(s)
25th Mar 202211:15 amRNS2019 Redemption Portfolio
22nd Mar 202211:00 amRNSCash Exit Payment
21st Mar 20223:02 pmRNSInterim Report and Accounts
2nd Mar 202210:23 amRNS2019 Redemption Portfolio
2nd Mar 202210:20 amRNSNet Asset Value(s)
23rd Feb 20224:40 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
21st Feb 202211:21 amRNSHolding(s) in Company
20th Jan 20225:22 pmRNSHolding(s) in Company
6th Jan 20225:06 pmRNS2019 Redemption Portfolio
6th Jan 20224:59 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.